International HIT-MED Registry (I-HIT-MED) for Children, Adolescents, and Adults With Medulloblastoma, Ependymoma, Pineoblastoma, CNS-primitive Neuroectodermal Tumours
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 500
- Locations
- 57
- Primary Endpoint
- Event free survival
Study Overview
Brief Summary
The I-HIT-MED registry registers clinical of children and adults with medulloblastoma, ependymoma, pineal tumours, or choroid plexus tumours in Germany and other countries that fulfil national ethic requirements for participation in this registry. These tumours are rare diseases, and many patients are treated outside of clinical trials. The I-HIT-MED registry allows collection of data und biological material from those patients, and provides a basis for standard treatment recommendations and counselling. It aims to improve the international cooperation and the medical knowledge in these rare diseases. Within the I-HIT-MED registry, it is a goal to maintain and improve networks for quality assurance in national groups where they are already established, and to support the implementation in national groups, where there is no quality assurance network yet.
Detailed Description
The following patients can be included in this registry:
Children and adults with
- Medulloblastoma (MB)
- Ependymoma
- Pineal Tumours
- Chroroid plexus tumours
Objectives of this registry:
To prospectively evaluate the clinical courses of patients with the eligible brain tumours, considering neuroradiological, pathological, and molecular / biological characteristics of the tumour and individual standard treatment data.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •all patients with above mentioned diagnosis of all ages (except for ependymoma WHO I°, pineal parenchymal tumour of intermediate differentiation and papillary tumour of the pineal region, who will be registered only if primary diagnosis was before the 18th birthday)
- •any localisation of the primary tumour
- •all clinical stages
- •First diagnosis after 01.01.2012
- •No inclusion into a prospective clinical trial for the same diagnosis, due to non-eligibility, national lack of trial approval, or individual refusal of participation.
- •Written informed consent for data transfer and tumour sample submission according to the laws of each participating country is necessary.
- •National and/ or local ethical committee approval according to the laws of each participating country is necessary.
Exclusion Criteria
- •Registration in another clinical trial for the same diagnosis (relapse is defined as a second diagnosis).
- •Lack of valid ethical committee approval.
Outcomes
Primary Outcomes
Event free survival
Time Frame: 10 years
Due to the explorative character of the registry, outcome measures are not strictly defined. We added the most common outcome measures.
Secondary Outcomes
- Pattern of relapse(10 years)
- Overall survival(10 years)